| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2000PNAS...97.1566L |
| P356 | DOI | 10.1073/PNAS.97.4.1566 |
| P932 | PMC publication ID | 26475 |
| P698 | PubMed publication ID | 10677500 |
| P5875 | ResearchGate publication ID | 235609535 |
| P50 | author | Colin Dunstan | Q43109492 |
| P2093 | author name string | Martin L | |
| Li J | |||
| Sun Y | |||
| Dunstan CR | |||
| Elliott R | |||
| McCabe S | |||
| Christensen K | |||
| Kaufman S | |||
| McCabe J | |||
| Tan HL | |||
| Boyle WJ | |||
| Yan XQ | |||
| Capparelli C | |||
| Lacey DL | |||
| Morony S | |||
| Hsu H | |||
| Fletcher F | |||
| Tarpley J | |||
| Scully S | |||
| Kostenuik P | |||
| Sarosi I | |||
| Van G | |||
| Juan SC | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif | Q28138697 | ||
| The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
| The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily | Q28291317 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation | Q28584897 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice | Q29618716 | ||
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| Modulation of osteoclast differentiation | Q35957509 | ||
| The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation | Q36635016 | ||
| Role of osteoblasts in hormonal control of bone resorption—A hypothesis | Q41551873 | ||
| A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. | Q41687961 | ||
| Effects of interleukin-1 on bone turnover in normal mice | Q43625701 | ||
| Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells | Q44919142 | ||
| Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
| Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. | Q52522634 | ||
| c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
| Bone and haematopoietic defects in mice lacking c-fos | Q58326969 | ||
| Functional analysis of the PTH/PTHrP network of ligands and receptors | Q77401471 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | calcium | Q706 |
| P304 | page(s) | 1566-1571 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | |
| P478 | volume | 97 |
| Q37589815 | A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse |
| Q57184035 | A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF |
| Q40367299 | A RANKL-inducible gene Znf216 in osteoclast differentiation |
| Q34567407 | A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss |
| Q36101308 | A changing landscape in castration-resistant prostate cancer treatment |
| Q46743257 | A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response |
| Q38058093 | A review of novel bacterial complex lipids: implications for the pathogenesis of apical periodontitis |
| Q46178292 | A toxicity profile of osteoprotegerin in the cynomolgus monkey |
| Q49050925 | A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis |
| Q48541886 | AIRE's CARD revealed, a new structure for central tolerance provokes transcriptional plasticity |
| Q36538837 | Abnormal lymphoid organ development in immunodeficient mutant mice. |
| Q50925640 | Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. |
| Q34356123 | Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements |
| Q45730626 | Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model |
| Q33783389 | Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice |
| Q35951939 | Adenosine A(2A) receptor ligation inhibits osteoclast formation. |
| Q34036039 | Adenosine and bone metabolism |
| Q37318849 | Advances in osteoclast biology resulting from the study of osteopetrotic mutations. |
| Q37850997 | Advances in osteoclast biology: old findings and new insights from mouse models |
| Q36327078 | Advances in the management of myeloma bone disease |
| Q92657238 | Aire-expressing ILC3-like cells in the lymph node display potent APC features |
| Q38271156 | Alternative pathways of osteoclastogenesis in inflammatory arthritis |
| Q36487325 | An HLA-DRB1-coded signal transduction ligand facilitates inflammatory arthritis: a new mechanism of autoimmunity |
| Q36567407 | An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice |
| Q28245637 | Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
| Q24805245 | Anti-cytokine therapy in chronic destructive arthritis |
| Q85746797 | Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model |
| Q57904725 | Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL) |
| Q35755287 | Antigen specificity and T-cell clonality in periodontal disease |
| Q38176010 | Apoptosis-associated uncoupling of bone formation and resorption in osteomyelitis |
| Q38570326 | Appropriate models for novel osteoporosis drug discovery and future perspectives |
| Q34107428 | Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. |
| Q35629551 | Aseptic loosening |
| Q64071625 | Association of Genetic Variants of , , and with Ankylosing Spondylitis Clinical Features in Taiwanese |
| Q42953444 | BAPTA-AM, an intracellular calcium chelator, inhibits RANKL-induced bone marrow macrophages differentiation through MEK/ERK, p38 MAPK and Akt, but not JNK pathways |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q24701763 | Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection |
| Q21195672 | Biology of recently discovered cytokines: interleukin-17--a unique inflammatory cytokine with roles in bone biology and arthritis |
| Q35878832 | Bone Is a Major Target of PTH/PTHrP Receptor Signaling in Regulation of Fetal Blood Calcium Homeostasis. |
| Q38257346 | Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones |
| Q36737006 | Bone disease in multiple myeloma |
| Q38136271 | Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer |
| Q45980823 | Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression. |
| Q57022699 | Bone protection by inhibition of microRNA-182 |
| Q38494091 | Bone turnover markers for early detection of fracture healing disturbances: A review of the scientific literature |
| Q37936285 | Bone, inflammation, and inflammatory bowel disease. |
| Q35511177 | Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling |
| Q52605959 | CHIP regulates bone mass by targeting multiple TRAF family members in bone marrow stromal cells. |
| Q35684029 | Calcium sensing and cell signaling processes in the local regulation of osteoclastic bone resorption |
| Q90239040 | Can injection of adipose stem cells to non-union zone increase bone union? Experimental rat study |
| Q36480304 | Canonical Notch activation in osteocytes causes osteopetrosis |
| Q45942621 | Carbonic anhydrase III protects osteocytes from oxidative stress. |
| Q41905947 | Cell-based osteoprotegerin therapy for debris-induced aseptic prosthetic loosening on a murine model |
| Q44058144 | Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones |
| Q47796415 | Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts |
| Q36017881 | Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone |
| Q34811184 | Chondromodulin I is a bone remodeling factor. |
| Q35928265 | Chronic inflammation in cancer development. |
| Q57251883 | Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22 |
| Q37642222 | Clinical and Genetic Advances in Paget's Disease of Bone: a Review |
| Q35184335 | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders |
| Q35092799 | Clinical utility of denosumab for treatment of bone loss in men and women |
| Q33906787 | Cloning and characterization of osteoclast precursors from the RAW264.7 cell line |
| Q36319940 | Col1a1-cre mediated activation of β-catenin leads to aberrant dento-alveolar complex formation |
| Q52859590 | Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. |
| Q33849260 | Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation |
| Q53569305 | Compressive mechanical stress promotes osteoclast formation through RANKL expression on synovial cells. |
| Q35084291 | Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development |
| Q36710160 | Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders |
| Q37038278 | Contributions to osteoclast biology from Japan |
| Q39147426 | Critical Role of LTB4/BLT1 in IL-23-Induced Synovial Inflammation and Osteoclastogenesis via NF-κB. |
| Q37286240 | Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation |
| Q35756845 | Crystal structure of RANK ligand involved in bone metabolism |
| Q27635130 | Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity |
| Q47131626 | Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation |
| Q40710871 | Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells |
| Q48109354 | Def6 Restrains Osteoclastogenesis and Inflammatory Bone Resorption. |
| Q37810423 | Denosumab for the Management of Postmenopausal Osteoporosis |
| Q37816261 | Denosumab: What's new? |
| Q43267044 | Denosumab: a promising drug for the prevention and treatment of osteoporosis |
| Q37307805 | Denosumab: an investigational drug for the management of postmenopausal osteoporosis |
| Q41997830 | Differentiating zones at periodontal ligament-bone and periodontal ligament-cementum entheses |
| Q38134658 | Diseases of the tooth: the genetic and molecular basis of inherited anomalies affecting the dentition |
| Q45325759 | Disruption of the transcription factor RBP-J results in osteopenia attributable to attenuated osteoclast differentiation |
| Q28743063 | Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength |
| Q36055881 | Do epigenetic marks govern bone mass and homeostasis? |
| Q91921619 | Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption? |
| Q47731229 | Downregulation of miR-106b attenuates inflammatory responses and joint damage in collagen-induced arthritis |
| Q33552815 | Early onset Paget's disease of bone caused by a novel mutation (78dup27) of the TNFRSF11A gene in a Chinese family |
| Q53742233 | Editorial: Inflammatory Osteoclasts: A Different Breed of Bone Eaters? |
| Q36383174 | Effect of radiation on the expression of osteoclast marker genes in RAW264.7 cells |
| Q42706677 | Effects of Brucine on the OPG/RANKL/RANK Signaling Pathway in MDA-MB-231 and MC3T3-E1 Cell Coculture System. |
| Q35589102 | Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis |
| Q33359381 | Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol |
| Q38664528 | Effects of pulsed electromagnetic fields on postmenopausal osteoporosis |
| Q47846447 | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing |
| Q45884566 | Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis |
| Q36099415 | Emerging and potential therapies for osteoporosis |
| Q36944034 | Emerging pharmacologic therapies for osteoporosis |
| Q37271460 | Eph receptors and ephrin signaling pathways: a role in bone homeostasis |
| Q83770424 | Epidemiology of osteoporosis |
| Q38661460 | Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells |
| Q36203317 | Estrogen, androgen, and the pathogenesis of bone fragility in women and men. |
| Q35860261 | Evidence that the kinase-truncated c-Src regulates NF-κB signaling by targeting NEMO. |
| Q34099162 | Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club |
| Q24299177 | Expression and function of RANK in human monocyte chemotaxis |
| Q44480300 | Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. |
| Q54322913 | Expression pattern changes and function of RANKL during mouse lymph node microarchitecture development. |
| Q86666626 | Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis |
| Q26863571 | Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8 |
| Q33635563 | Fracture healing is accelerated in the absence of the adaptive immune system. |
| Q37730952 | Functions of nuclear factor kappaB in bone |
| Q33788192 | Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo. |
| Q55019516 | Gap junctional communication is involved in differentiation of osteoclasts from bone marrow and peripheral blood monocytes. |
| Q37968682 | Genetic determinants of Paget's disease of bone |
| Q30168513 | Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival |
| Q29617421 | Genetic regulation of osteoclast development and function |
| Q35552797 | Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone |
| Q38208716 | Giant cell tumor of bone: current treatment options |
| Q37611651 | Growth-plate cartilage in chronic renal failure |
| Q30354085 | Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. |
| Q64264445 | Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice |
| Q39212169 | Heterotrimeric G proteins in the control of parathyroid hormone actions |
| Q50211924 | Histological Analysis of Early Osteolysis in Total Ankle Arthroplasty |
| Q36572545 | Hodgkin's lymphoma: molecular targets and novel treatment strategies |
| Q91992936 | Hypoalbuminemia differently affects the serum bone turnover markers in hemodialysis patients |
| Q36403428 | IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation |
| Q37497970 | IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. |
| Q50771304 | IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. |
| Q51027178 | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL |
| Q46372900 | IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. |
| Q35237706 | Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis |
| Q36924500 | Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration |
| Q92866142 | Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model |
| Q39085876 | Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice |
| Q37317215 | Immune regulation of bone loss by Th17 cells. |
| Q37590011 | Immunohistochemical expression of Src protein in peripheral and central giant cell granulomas of the jaws. |
| Q36107934 | Immunoregulation of bone remodelling |
| Q38987211 | Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies |
| Q40655044 | Induction of Osteoclast Differentiation by Runx2 through Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin Regulation and Partial Rescue of Osteoclastogenesis in Runx2–/– Mice by RANKL Transgene |
| Q35643989 | Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? |
| Q57804323 | Inflammation Is The Main Determinant of Low Bone Mineral Density in Pediatric Inflammatory Bowel Disease |
| Q36497982 | Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function |
| Q38852509 | Inflammatory bone loss in experimental periodontitis induced by Aggregatibacter actinomycetemcomitans in interleukin-1 receptor antagonist knockout mice. |
| Q39343563 | Inflammatory osteolysis: a conspiracy against bone |
| Q98613272 | Inhibition of Axin1 in osteoblast precursor cells leads to defects in postnatal bone growth through suppressing osteoclast formation |
| Q51573211 | Inhibition of the osteoclast activity with the application of recombinant murine RANK protein. |
| Q42176661 | Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients |
| Q38752770 | Interaction of Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) and Vav3 in the Receptor Activator of Nuclear Factor κB (RANK) Signaling Complex Enhances Osteoclastogenesis. |
| Q37270187 | Interactions between immune and bone cells: new insights with many remaining questions |
| Q54704161 | Interactions of the tooth and bone during development. |
| Q39637547 | Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor κB ligand |
| Q54572718 | Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. |
| Q40727130 | Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors |
| Q54361910 | Interleukin-19 blockade attenuates collagen-induced arthritis in rats. |
| Q35557866 | Invited Review: Pathogenesis of osteoporosis |
| Q28202653 | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis |
| Q59645637 | Involvement of soluble receptor activator of nuclear factor-κB ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis |
| Q35093569 | Japanese medaka: a non-mammalian vertebrate model for studying sex and age-related bone metabolism in vivo. |
| Q24673624 | Jun Dimerization Protein 2 (JDP2), a Member of the AP-1 Family of Transcription Factor, Mediates Osteoclast Differentiation Induced by RANKL |
| Q44068969 | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis |
| Q40547452 | LOX Fails to Substitute for RANKL in Osteoclastogenesis |
| Q53221110 | Lineage-committed osteoclast precursors circulate in blood and settle down into bone. |
| Q52012973 | Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. |
| Q46196784 | Lipoproteins are an important bacterial component responsible for bone destruction through the induction of osteoclast differentiation and activation. |
| Q46359470 | Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats |
| Q34133595 | M-CSF mediates TNF-induced inflammatory osteolysis |
| Q38211359 | Managing bone metastases and reducing skeletal related events in prostate cancer |
| Q52578848 | Mechanisms involved in normal and pathological osteoclastogenesis. |
| Q40257615 | Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative. |
| Q37106639 | Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets |
| Q46282430 | Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition |
| Q38804471 | Microgravity Stress: Bone and Connective Tissue |
| Q40756889 | Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling |
| Q35054970 | Minireview: nuclear receptor regulation of osteoclast and bone remodeling |
| Q38794453 | Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues |
| Q37034768 | Mitogen-inducible gene-6 partly mediates the inhibitory effects of prenatal dexamethasone exposure on endochondral ossification in long bones of fetal rats |
| Q35939914 | Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis. |
| Q34106530 | Molecular control of bone remodeling and osteoporosis |
| Q37169549 | Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis |
| Q98465934 | Molecular mechanisms and clinical management of cancer bone metastasis |
| Q35084886 | Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB |
| Q49589290 | Morphological characteristics of osteopetrosis |
| Q34390754 | Mouse models of abnormal skeletal development and homeostasis |
| Q42795870 | Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis |
| Q57533061 | Mutation of macrophage colony stimulating factor (Csf1) causes osteopetrosis in the tl rat |
| Q43883711 | Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity |
| Q37363042 | NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism |
| Q34264609 | NF-kappaB signaling and human disease |
| Q42009786 | NF-kappaB2 (p100) limits TNF-alpha-induced osteoclastogenesis |
| Q37449635 | NF-κB signaling and bone resorption |
| Q35260971 | NF-κB-Mediated Regulation of Osteoclastogenesis |
| Q52018491 | NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K. |
| Q30157499 | NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism |
| Q45856471 | NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts |
| Q91896658 | Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation |
| Q47915117 | Naringenin inhibits osteoclastogenesis through modulation of helper T cells-secreted IL-4. |
| Q28307600 | Negative autoregulation of RANKL and c-Src signaling in osteoclasts |
| Q40472853 | Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. |
| Q111019276 | Neuropilin‐1‐Mediated SARS‐CoV‐2 Infection in Bone Marrow‐Derived Macrophages Inhibits Osteoclast Differentiation |
| Q64235920 | New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis |
| Q37748586 | New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. |
| Q36539657 | New roles of osteoblasts involved in osteoclast differentiation |
| Q61814977 | Ninjurin1 positively regulates osteoclast development by enhancing the survival of prefusion osteoclasts |
| Q38636476 | Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases |
| Q34568952 | Novel therapeutic targets in osteoporosis |
| Q36623081 | Novel therapies for rheumatoid arthritis |
| Q26853017 | Nuclear receptors in bone physiology and diseases |
| Q35557947 | Oestrogen deficiency modulates particle-induced osteolysis |
| Q36651643 | Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? |
| Q34372493 | Origin, development, and homeostasis of tissue-resident macrophages |
| Q90631432 | Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development |
| Q36542861 | Osteoblast lineage-specific effects of notch activation in the skeleton |
| Q37790176 | Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis |
| Q29547556 | Osteoclast differentiation and activation |
| Q28593804 | Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha |
| Q39646430 | Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism |
| Q36324916 | Osteoclast precursors, RANKL/RANK, and immunology |
| Q37118763 | Osteoclasts - the innate immune cells of the bone |
| Q35755039 | Osteoclasts: New Insights |
| Q24683898 | Osteoclasts: what do they do and how do they do it? |
| Q88248494 | Osteoimmunology |
| Q37626412 | Osteoimmunology and the effects of the immune system on bone |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q37544448 | Osteoimmunology: crosstalk between the immune and bone systems |
| Q37235713 | Osteoimmunology: cytokines and the skeletal system |
| Q24655113 | Osteoimmunology: interactions of the bone and immune system |
| Q38123371 | Osteopetrosis: genetics, treatment and new insights into osteoclast function. |
| Q34178759 | Osteoporosis and gastrointestinal disease |
| Q28505310 | Osteoporotic bone formation in mice lacking tob2; involvement of Tob2 in RANK ligand expression and osteoclasts differentiation |
| Q34560598 | Osteoprotegerin |
| Q38409333 | Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease |
| Q35612713 | Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report |
| Q79848042 | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation |
| Q81739887 | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis |
| Q36319635 | Osteoprotegerin as a potential therapy for osteoporosis |
| Q82723955 | Osteoprotegerin as a potential therapy for osteoporosis |
| Q36150705 | Osteoprotegerin deficiency results in disruption of posterofrontal suture closure in mice: implications in nonsyndromic craniosynostosis |
| Q34079327 | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
| Q35789185 | Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis |
| Q92799706 | Osteoprotegerin reduces osteoclast resorption activity without affecting osteogenesis on nanoparticulate mineralized collagen scaffolds |
| Q36029217 | Paget disease of bone |
| Q34546256 | Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling |
| Q35568480 | Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK. |
| Q30494322 | Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis |
| Q73197583 | Participation of protein kinase C beta in osteoclast differentiation and function |
| Q37187646 | Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. |
| Q38006389 | Pathogenesis of Paget disease of bone. |
| Q34131375 | Pathogenesis of bone fragility in women and men. |
| Q46224909 | Pathogenesis of myeloma bone disease |
| Q36090203 | Pathological role of osteoclast costimulation in arthritis-induced bone loss. |
| Q35122555 | Perspectives on osteoporosis in pediatric inflammatory bowel disease |
| Q54379479 | Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. |
| Q37863538 | Phosphatidylserine-containing liposomes: potential pharmacological interventions against inflammatory and immune diseases through the production of prostaglandin E(2) after uptake by myeloid derived phagocytes |
| Q37810596 | Physiology and pathophysiology of the RANKL/RANK system |
| Q34685145 | Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function. |
| Q39100666 | Platelet-activating factor receptor blockade ameliorates Aggregatibacter actinomycetemcomitans-induced periodontal disease in mice |
| Q38514192 | Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. |
| Q34600281 | Protection by salidroside against bone loss via inhibition of oxidative stress and bone-resorbing mediators |
| Q36404753 | Protective and destructive immunity in the periodontium: Part 2--T-cell-mediated immunity in the periodontium |
| Q38878942 | Proteomic approaches to study osteoclast biology |
| Q28302165 | Pulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/β-catenin signaling-associated mechanism |
| Q51426261 | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. |
| Q36600255 | RANK ligand inhibition with denosumab for the management of osteoporosis |
| Q36078073 | RANK, RANKL and osteoprotegerin in arthritic bone loss |
| Q35053943 | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma |
| Q26747442 | RANK-RANKL signalling in cancer |
| Q35837418 | RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations |
| Q27674275 | RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor |
| Q47256563 | RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. |
| Q36898545 | RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease |
| Q28570898 | RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies |
| Q59806646 | RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation |
| Q37241264 | RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases |
| Q39679829 | RANKL-RANK signaling regulates expression of xenotropic and polytropic virus receptor (XPR1) in osteoclasts |
| Q59806653 | RANKL-RANK signaling regulates osteoblast differentiation and bone formation |
| Q39761712 | RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis |
| Q28308042 | RANKL/RANK-beyond bones |
| Q90152388 | RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling |
| Q37286493 | RANKing c-Jun in osteoclast development |
| Q34034613 | Rank Protein Immunolabeling during Bone-Implant Interface Healing Process |
| Q50215136 | Recent advances in osteoclast biology. |
| Q34333628 | Receptor Activator of NF-κB (RANK) Cytoplasmic IVVY535–538 Motif Plays an Essential Role in Tumor Necrosis Factor-α (TNF)-mediated Osteoclastogenesis |
| Q40633180 | Receptor Activator of NF-κB Ligand Stimulates Recruitment of SHP-1 to the Complex Containing TNFR-Associated Factor 6 That Regulates Osteoclastogenesis |
| Q47109113 | Receptor Activator of NF-κB Orchestrates Activation of Antiviral Memory CD8 T Cells in the Spleen Marginal Zone. |
| Q28740575 | Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients |
| Q53655018 | Receptor activator of NF-κB ligand arrests bone growth and promotes cortical bone resorption in growing rats |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q34086847 | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases |
| Q38884628 | Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling. |
| Q37884121 | Regulation of bone by the adaptive immune system in arthritis |
| Q34250588 | Regulation of bone cell development and function: implication for renal osteodystrophy. |
| Q36568516 | Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways |
| Q28830055 | Regulation of osteoblast development by Bcl-2-associated athanogene-1 (BAG-1) |
| Q34728971 | Regulatory mechanisms of osteoblast and osteoclast differentiation |
| Q40348456 | Relaxin stimulates leukocyte adhesion and migration through a relaxin receptor LGR7-dependent mechanism |
| Q40598376 | Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities |
| Q39060253 | Reproducible quantification of osteoclastic activity: characterization of a biomimetic calcium phosphate assay |
| Q46559560 | Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al. |
| Q93165466 | Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy |
| Q33719241 | Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK |
| Q36272906 | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
| Q36324975 | Rheumatic diseases: the effects of inflammation on bone |
| Q37362091 | Role of MKP-1 in osteoclasts and bone homeostasis |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q35165886 | Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications |
| Q97419698 | Role of TNF-α and FGF-2 in the Fracture Healing Disorder of Type 2 Diabetes Model Induced by High Fat Diet Followed by Streptozotocin |
| Q36177501 | Roles for NF-kappaB and c-Fos in osteoclasts |
| Q30009398 | SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss |
| Q58903538 | Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab |
| Q47446256 | Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo |
| Q42052780 | Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials |
| Q34090842 | Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. |
| Q72991541 | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation |
| Q36043987 | Signal peptide mutations in RANK prevent downstream activation of NF-κB. |
| Q26766637 | Signaling Pathways in Osteoclast Differentiation |
| Q38138849 | Signaling between tumor cells and the host bone marrow microenvironment. |
| Q35587493 | Signaling pathways in osteogenesis and osteoclastogenesis: Lessons from cranial sutures and applications to regenerative medicine. |
| Q40463168 | Soluble RANKL Cleaved from Activated Lymphocytes by TNF-α-Converting Enzyme Contributes to Osteoclastogenesis in Periodontitis. |
| Q48208205 | Spatholobus suberectus inhibits osteoclastogenesis and stimulates chondrogenesis |
| Q34988281 | Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss |
| Q37379999 | Strontium inhibits titanium particle-induced osteoclast activation and chronic inflammation via suppression of NF-κB pathway. |
| Q37251736 | Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro |
| Q28579644 | Synergistic role of hydroxyapatite nanoparticles and pulsed electromagnetic field therapy to prevent bone loss in rats following exposure to simulated microgravity |
| Q44967081 | Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen |
| Q54230593 | TGF-β in dentin matrix extract induces osteoclastogenesis in vitro. |
| Q35750113 | TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression |
| Q39287117 | TNF and Bone Remodeling |
| Q30743828 | TNF ligands and receptors in autoimmunity: an update |
| Q34542205 | TNF ligands and receptors--a matter of life and death |
| Q37413745 | TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand |
| Q35760837 | TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. |
| Q55139784 | TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway. |
| Q40641517 | TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor |
| Q35022687 | Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss |
| Q34902134 | Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy |
| Q37946702 | Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma |
| Q36649905 | The Dmp1-SOST Transgene Interacts With and Downregulates the Dmp1-Cre Transgene and the Rosa(Notch) Allele |
| Q37485598 | The First Scube3 Mutant Mouse Line with Pleiotropic Phenotypic Alterations. |
| Q64062131 | The Molecular Mechanism of Vitamin E as a Bone-Protecting Agent: A Review on Current Evidence |
| Q89314569 | The Osteoclast in Bone Metastasis: Player and Target |
| Q64102143 | The RANKL-RANK Axis: A Bone to Thymus Round Trip |
| Q28203717 | The TNF and TNF receptor superfamilies: integrating mammalian biology |
| Q53807792 | The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer. |
| Q51040187 | The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. |
| Q42098333 | The effect of osteoprotegerin gene modification on wear debris-induced osteolysis in a murine model of knee prosthesis failure |
| Q26995207 | The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction |
| Q35088756 | The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice |
| Q80187296 | The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis |
| Q50651156 | The mineral dissolution function of osteoclasts is dispensable for hypertrophic cartilage degradation during long bone development and growth. |
| Q24297505 | The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis |
| Q28142247 | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development |
| Q37136324 | The pathogenesis of the bone disease of multiple myeloma. |
| Q40756948 | The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation |
| Q37598359 | The role of T helper type 17 cells in inflammatory arthritis |
| Q24805207 | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. |
| Q35246409 | The role of polyunsaturated ω-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1) in bone preservation |
| Q36491430 | The role of the bone microenvironment in skeletal metastasis. |
| Q36324969 | The role of the immune system in the pathophysiology of osteoporosis |
| Q36494408 | The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism |
| Q38841107 | The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth |
| Q44970710 | The vital osteoclast: how is it regulated? |
| Q37396554 | Therapeutic potentials of naringin on polymethylmethacrylate induced osteoclastogenesis and osteolysis, in vitro and in vivo assessments. |
| Q43855560 | Thyroid status affects number and localization of thyroid hormone receptor expressing mast cells in bone marrow |
| Q37074250 | Towards a better understanding and new therapeutics of osteopetrosis |
| Q38290706 | Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. |
| Q33713146 | Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice |
| Q36902828 | Treatment strategies for bone disease |
| Q46698043 | Triiodothyronine (T3) does not induce Rankl expression in rat Ros 17/2.8 cells |
| Q44427920 | Tumor necrosis factor stimulates osteoclastogenesis from human bone marrow cells under hypoxic conditions |
| Q73853199 | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture |
| Q36380499 | Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity |
| Q53945794 | Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. |
| Q33775139 | Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation |
| Q26785501 | Use of Animal Models in Understanding Cancer-induced Bone Pain |
| Q34590536 | Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio |
| Q45298906 | Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. |
| Q44534331 | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand |
| Q64950655 | XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression. |
| Q39609021 | Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis |
| Q51306052 | [6]-Gingerol induces bone loss in ovary intact adult mice and augments osteoclast function via the transient receptor potential vanilloid 1 channel. |
| Q84542806 | [Molecular physical medicine] |
| Q53543277 | [Notch signaling promotes receptor activator of nuclear factor kappa B ligand-induced ostoclastogenesis of RAW264.7 cells in vitro]. |
| Q33912421 | siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption |
| Q38807300 | uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis |
Search more.